Abstract: Slide Presentations |

A Full Beta2-Agonist is More Effective Than a Partial Agonist in Acute Severe Asthma FREE TO VIEW

Remzi Bag, MD; Janice Zimmerman, MD; Amir Sharafkhaneh, MD; Burton Dickey, MD; Nicola A. Hanania, MBBS*
Author and Funding Information

Baylor College of Medicine, Houston, TX


Chest. 2004;126(4_MeetingAbstracts):722S. doi:10.1378/chest.126.4_MeetingAbstracts.722S
Text Size: A A A
Published online


PURPOSE:  Inhaled beta2-agonists are a key component of the initial treatment of acute asthma. Guidelines recommend repeated doses of albuterol for emergency treatment of acute asthma, but many patients show little or no response to this regimen. This finding may in part be explained by the fact that albuterol is a weak partial agonist (low intrinsic efficacy). Our study examines the efficacy and safety of isoproterenol (full agonist) versus albuterol in adults presenting with acute severe asthma.

METHODS:  In a double-blind study, adults (18-50 years) presenting with acute severe asthma (FEV1 < 50%) were randomized to albuterol (7.5 mg/hour) (n = 10, mean % predicted FEV1 = 37%) or isoproterenol (7.5 mg/hour) (n = 9, mean % predicted FEV1 = 33.3%) administered for two hours by continuous nebulization. Efficacy measures and safety parameters were collected.

RESULTS:  Both groups had similar baseline characteristics. The improvements in baseline FEV1 at 60 and 120 minutes were significantly higher in subjects receiving isoproterenol compared to those receiving albuterol (44.2 vs. 17.4% and 62.6 vs. 23.5%, respectively, p < 0.05). The change in Modified Borg scores was also significantly greater in subjects receiving isoproterenol at 45, 60, 90, 105 and 120 minutes (p < 0.01). Both treatments were well tolerated. However, the change in pulse rate from baseline was significantly higher in the isoproterenol group compared to the albuterol group (22.4% vs. 6.9%, respectively, p<0.05). The decrease in serum potassium from baseline was also significantly greater in the isoproterenol group compared to the albuterol group (-0.52 vs. -0.07 meq/L, respectively, p <0.05).

CONCLUSION:  Our data suggest that the intrinsic efficacy of a beta2-agonist is an important determinant of the physiologic and symptomatic response in acute severe asthma.

CLINICAL IMPLICATIONS:  Patients with acute severe asthma who have an inadequate response to an agonist of low intrinsic efficacy may benefit from use of an agonist of a higher intrinsic efficacy.

DISCLOSURE:  N.A. Hanania, None.

Monday, October 25, 2004

2:30 PM- 4:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543